bimagrumab and tirzepatide Update from #ADA2025 : 🧬 Bimagrumab Targets Activin Pathway in Obesity – Dual Action Molecule 👨‍⚕️ #ADA2025 #Obesity #WeightLoss 🔹 What is Bimagrumab? A monoclonal antibody that blocks activin type II 📌 Why Isn't Anyone Talking

See which oral GLP-1 is easier to take, and which delivers stronger weight loss results

Should I take semaglutide on an empty stomach

Biopharma bigwigs Eli Lilly and Novo Nordisk are upping capacity to meet the rising demands of GLP-1 drugs.

Together, these presentations reflect continued progress across the elecoglipron clinical program and its potential as a once-daily oral GLP-1 receptor agonist for people living with obesity, overweight, or type 2 diabetes

Conclusion Semaglutide confers robust cardiovascular protection in T2D, with amplified benefits in patients with comorbid CKD

Secondary progressive MS: RRMS that later progresses steadily